Collet Carlos, Sotomi Yohei, Cavalcante Rafael, Asano Taku, Miyazaki Yosuke, Tenekecioglu Erhan, Kistlaar Pieter, Zeng Yaping, Suwanasson Pannipa, de Winter Robbert J, Nieman Koen, Serruys Patrick W, Onuma Yoshinobu
Cardiology Department, Academic Medical Centre, Amsterdam, The Netherlands.
ThoraxCenter, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Int J Cardiovasc Imaging. 2017 Mar;33(3):431-439. doi: 10.1007/s10554-016-1018-6. Epub 2016 Nov 28.
To establish the accuracy of coronary computed tomography angiography (CTA) for in-scaffold quantitative evaluation with optical coherence tomography (OCT) as a reference. The translucent backbone of the bioresorbable scaffold allow us to evaluate non-invasively the coronary lumen with coronary CTA. In the ABSORB first-in-man studies, coronary CTA was shown to be feasible for quantitative luminal assessment. Nevertheless, a comparison with an intravascular modality with higher resolution has never been performed. In the ABSORB Cohort B trial, 101 patient with non-complex lesions were treated with the fully biodegradable vascular scaffold. For this analysis, all patients who underwent coronary CTA at 18 months and OCT within ±180 days were included. Coronary CTA and OCT data were analysed at an independent core laboratory for quantitative cross-sectional luminal dimensions. The primary objective was the accuracy and precision of coronary CTA for in-scaffold minimal lumen area assessment, with OCT as a reference. Among the 101 patients of the ABSORB Cohort B trial, 35 underwent both OCT and coronary CTA. The feasibility of quantitative evaluation was 74%. In the scaffolded segment, coronary CTA underestimated minimal lumen area by 9.8% (accuracy 0.39 mm, precision 1.0 mm, 95% limits of agreement -1.71 to 2.50 mm). A similar level of agreement was observed in the non-scaffolded segment. Compared to OCT, coronary CTA appears to be accurate for the estimation of in-scaffold luminal areas, with no difference compared to the non-scaffolded region.
以光学相干断层扫描(OCT)为参照,确定冠状动脉计算机断层扫描血管造影(CTA)用于支架内定量评估的准确性。生物可吸收支架的半透明主干使我们能够通过冠状动脉CTA对冠状动脉管腔进行无创评估。在ABSORB首次人体研究中,冠状动脉CTA已被证明可用于管腔定量评估。然而,从未与分辨率更高的血管内成像方式进行过比较。在ABSORB队列B试验中,101例患有非复杂性病变的患者接受了完全可生物降解血管支架治疗。对于本分析,纳入了所有在18个月时接受冠状动脉CTA检查且在±180天内接受OCT检查的患者。冠状动脉CTA和OCT数据在独立的核心实验室进行分析,以获取管腔横截面尺寸的定量数据。主要目的是以OCT为参照,确定冠状动脉CTA用于支架内最小管腔面积评估的准确性和精确性。在ABSORB队列B试验的101例患者中,35例同时接受了OCT和冠状动脉CTA检查。定量评估的可行性为74%。在支架置入段,冠状动脉CTA低估最小管腔面积9.8%(准确性0.39 mm,精确性1.0 mm,95%一致性界限为-1.71至2.50 mm)。在非支架置入段观察到了类似的一致性水平。与OCT相比,冠状动脉CTA在估计支架内管腔面积方面似乎是准确的,与非支架置入区域相比无差异。